tbuckley/cabot-search huggingface dataset:
Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) Guideline
Authors: Cesare Hassan, Piotr Wysocki, Lorenzo Fuccio, Thomas Seufferlein, Mário Dinis-Ribeiro, Catarina Brandão, Jaroslaw Regula, Leonardo Frazzoni, Maria Pellise, Sergio Alfieri, Evelien Dekker, Rodrigo Jover, Gerardo Rosati, Carlo Senore, Cristiano Spada, Ian Gralnek, Jean-Marc Dumonceau, Jeanin van Hooft, Eric van Cutsem, Thierry Ponchon
Journal: Endoscopy (2019)

Correction to: Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) GuidelineEndoscopy eFirstDOI: 10.1055/a-0831-2522
Abstract P3-08-58: Ratio of CD8 +/ FOXP3, number of FOXP3 + cells and the presence of PTEN labeling in tumor cells and association with survival in triple negative breast cancer
Authors: Monique C Tavares, Geraldine E Lima, Cristina D Sampaio, Victor P Andrande, Daniel G Gonçalves, Mariana P Macedo, Vladmir C Lima
Journal: Cancer Research (2020)

Abstract Introduction: Triple-negative mammary carcinomas (CMTN) correspond to about 15 to 20%, the subtype being more aggressive when compared to the others. The interaction between immune system cells and cancer plays a crucial role in tumor development and progression. However, it is still unclear whether the presence of CD8 cytotoxic lymphocytes provides any prognostic information in breast cancer. Objective: To evaluate the prognostic significance of tumor-associated FOXP3 regulatory T cells (Tregs) and CD8 cytotoxic T lymphocytes (CTLs) in invasive breast carcinomas Method: This is an observational, descriptive retrospective cohort study were evaluated 76 patients diagnosed with non metastatic (stages I, II and III) TNBC. A tissue microarray (TMA) was constructed containing two cores from each tumor block. The expression of CD4, CD8, FOXP3, CD20, CD68, CD163, PD-1, PD-L1, PTEN and phosphoSTAT1 was determined by immunohistochemistry in the TMA. Results: We observed that the inflammatory infiltrate in TNBC is enriched for M2 macrophages and T lymphocytes (CD4+, CD8+ and FOXP3+). In our sample, we observed better survival associated with a higher CD8 + (p = 0.054) and CD4 + (p = 0.082) cell counts, but with no statistical significance in both situations. However, when we analyzed the association of overal survival (OS) with the ratio between the number of CD8 + cells and FOXP3 + (p = 0.007) and CD4 + and FOXP3 + (p = 0.034) and CD4 (p = 0.058) cells, we found that a higher relative proportion of CD8 + or CD4 + lymphocytes in relation to lymphocytes FOXP3 + was associated with an increase in OS. Together, these data suggest that infiltration by T lymphocytes into the tumor microenvironment should exhibit antirumor activity and promote growth control and tumor progression, as opposed to events favoring immunosuppression (regulatory lymphocyte infiltration). The number of FOXP3+ cells and the presence of PTEN staining in tumor cells were associated with OS. Conclusion: We did not observe improvement in survival, with an increase in CD8 and CD4 alone, so we found an improvement in survival, the higher the ratio between CD8 / FOXP3 being statistically significant. The number of FOXP3+ cells and the presence of PTEN staining in tumor cells were associated with OS. Citation Format: Monique C Tavares, Geraldine E Lima, Cristina D Sampaio, Victor P Andrande, Daniel G Gonçalves, Mariana P Macedo, Vladmir C Lima. Ratio of CD8 +/ FOXP3, number of FOXP3 + cells and the presence of PTEN labeling in tumor cells and association with survival in triple negative breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-08-58.
PROCEDURAL AND CLINICAL OUTCOMES WITH THE DIAMONDBACK 360® ORBITAL ATHERECTOMY SYSTEM: A CLASSIC CROWN WITH GLIDEASSIST® AND VIPERWIRE ADVANCE® FLEXTIP
Authors: Yutaka Tanaka, Shohei Yokota, Takahiro Hayashi, Hirokazu Miyashita, Hiroaki Yokoyama, Kazuki Tobita, Koki Shishido, Shingo Mizuno, Futoshi Yamanaka, Saeko Takahashi, Shigeru Saito
Journal: Journal of the American College of Cardiology (2020)
T1 MAPPING FOR MYOCARDIAL TISSUE EVALUATION IN PATIENTS WITH ISCHEMIA AND STABLE CORONARY ARTERY DISEASE: MASS V-TRIAL STUDY GROUP
Authors: Matheus Ribeiro, Whady Hueb, Paulo Rezende, Carlos Rochitte, Cesar Nomura, Thamara Morais, Eduardo Gomes Lima, Gustavo Boros, Fernando Faglioni Ribas, Felipe Pereira Camara Carvalho, Guilherme Carvalho, Carlos Serrano, Jose Ramires, Roberto Kalil-Filho
Journal: Journal of the American College of Cardiology (2020)
Comprehensive analysis of serum N-glycans as a biomarker for breast cancer.
Authors: Takayuki Ueno, Fumiaki Sato, Nobuhiko Shinkura, Taichi Aihara, Masao Fukushima, Masaru Sekijima, Masakazu Toi
Journal: Journal of Clinical Oncology (2012)

e21031 Background: Early detection of breast cancer is an important aspect to improve therapeutic outcome. Serum biomarkers have a number of advantages including less invasiveness and possible application for monitoring. Glycans are involved in many biological processes including cancer progression and promising candidates for cancer biomarker. Methods: Sera were collected from 54 patients with operable breast cancer and 118 healthy volunteers. N-glycans were isolated by BlotGlyco (Sumitomo Bakelite Co., LTD, Japan) and N-glycan profile was obtained by MALDI-TOF MS. The principal component analysis (PCA) was performed by SIMCA-P+ ver.12 (Umetrics). N-glycan compositions were estimated from mass spectra using 'GlycoMod' database. Results: Fifty-four pts (age: 31-78) and 118 healthy females (age: 29-73) were enrolled. The tumor size was between 9 and 107mm (median 29mm). Twenty six pts (48%) had lymph node involvement. Fifty three peaks of N-glycans were observed in more than 95% of the samples and utilized for the analyses. By PCA, no distinction was observed in sera form breast cancer pts in terms of the tumor size, hormone receptor status and HER2 status. The N-glycan signature to identify cancer pts was created based on the PCA. The signature categorized samples into three groups: cancer, healthy and border groups. Half of the samples (even registration number) were used for training and the rest for validation. In the validation cohort, 18 (66.7%) of 27 pts were categorized into the cancer group and 9 were into the border group. Forty-seven (79.7%) of 59 volunteers were categorized into the healthy group and 11 were into the border group. When the border group was included in the cancer group, the sensitivity was 100% (27 of 27 pts in the cancer group) and the specificity was 79.7% (47 of 59 volunteers in the healthy group). Conclusions: The comprehensive analysis of N-glycans in sera enabled the creation of the N-glycan signature to distinguish between breast cancer pts and healthy females with high sensitivity and high specificity. Confirmative studies are warranted.
Targeted agent (TA) use at the end of life (EOL).
Authors: Meghan Sri Karuturi, Kimberson Tanco, Jung Hye Kwon, Tao Zhang, Wadih Rhondali, Jung Hun Kang, Gary B. Chisholm, Eduardo Bruera, David Hui
Journal: Journal of Clinical Oncology (2012)

e19603 Background: Chemotherapy in the last days of life has questionable benefit and has been proposed as an indicator of poor quality of EOL care. The use of TAs at the EOL has not been examined. We determined the proportion and predictors of TA use in the last 30 days of life. Methods: All adult patients in the Houston area who died of advanced cancer between 9/1/2009 and 2/28/2010 while under the care of our institution were included. We collected baseline demographics and data on chemotherapy and TAs. Multivariate logistic regression was used to identify predictors of targeted therapy use. Results: 912 patients were included: average age 63 (range 21-98), female 49%, Caucasian 63%. Within the last 30 and 14 days of life, 117 (13%) and 56 (6%) patients received TAs, respectively, while 148 (16%) and 65 (7%) received chemotherapy. The interval between last TA use and death was 49 (21-106) days. Regimens given in the last 30 days of life included a median of 2 (1-2) chemotherapeutic/targeted agents, and the most common TAs were erlotinib (N=22), bevacizumab (N=19), rituximab (N=9), gemtuzumab (N=9) and temsirolimus (N=8). 43/117 (37%) patients who received TAs within the last 30 days of life had concurrent chemotherapy. In multivariate analysis, younger age and hematologic malignancies were associated with increased TA use (Table). Conclusions: TAs were used as often as chemotherapy at the EOL, particularly among younger patients and those with hematologic malignancies. Use of TAs in the last 30 days of life may have implications for quality of EOL care. [Table: see text]
Impact of adjuvant anti-VEGF therapy on treatment-related pseudoprogression in patients with newly diagnosed glioblastoma receiving chemoradiation with or without anti-VEGF therapy.
Authors: Marco C Pinho, Pavlina Polaskova, Dominique Jennings, Patrick Y. Wen, Rakesh K. Jain, A. Gregory Sorensen, Elizabeth Robins Gerstner, Tracy Batchelor
Journal: Journal of Clinical Oncology (2012)

2025 Background: Chemoradiation (CRT) can significantly modify the appearance of glioblastoma (GBM) on MRI, especially within the 3-month window after CRT. Pseudoprogression (PsP) is an increasingly recognized phenomenon in this scenario, and is thought to be secondary to increased permeability of the tumor vessels from irradiation, possibly enhanced by temozolomide (TMZ). We sought to determine if the addition of a VEGF signaling inhibitor (cediranib) during and after CRT had an impact on the frequency of PsP, by comparing two groups of patients with newly diagnosed GBMs. Methods: Two groups of patients enrolled in IRB-approved trials underwent serial MRIs at baseline, weekly during CRT and monthly thereafter. The control group received radiation plus TMZ, while the other group (CED) also received cediranib until progression (which was defined by RANO criteria) or toxicity. Patients that progressed up to 3 months after CRT were considered to have apparent progression (AP) and kept on treatment. Lesions that subsequently stabilized/regressed were classified as PsP, while those that maintained growth despite treatment were classified as true early progression (EP). Results: Forty patients were enrolled in CED and 11 as controls. Ten patients from CED and three controls were excluded due to treatment discontinuation before 3 months (drug-related toxicity and enrollment in post-CRT trials respectively). Three patients in CED (6%) had AP (all confirmed as EP) and no patients fulfilled criteria for PsP. Six patients from control (54%) had AP; 3 (27%) were eventually classified as EP and 3 (27%) as PsP. The frequency of PsP was significantly higher in the control group (p=0.0086). Conclusions: The addition of a VEGF inhibitor as part of adjuvant treatment in this cohort of glioblastoma patients prevented the development of early treatment-related effects (PsP). Suppressing the edema and mass effect that accompanies PsP may improve the tolerability of treatment. Additionally, this effect may be exploited as a strategy to make chemoradiation feasible in patients with large, unresectable tumors and/or poor baseline performance status.
Treatment patterns in patients with early and advanced malignant melanoma.
Authors: Victor M. Gastanaga, Jan E. Lethen, Ari M. Vanderwalde, Lori A. Cyprien, Michael A. Kelsh, Joel D. Kallich
Journal: Journal of Clinical Oncology (2013)

9083 Background: We seek to characterize tx patterns for patients (pts) with early stage (ES) and advanced stage (AS) malignant melanoma (MM). MarketScan is a large insurance claims database with complete diagnosis (dx) and tx information. Methods: Using MarketScan data, pts were identified between Jan 2001 and Jun 2011 using ≥1 inpatient or ≥2 outpatient MM ICD9 codes ≥6 weeks apart. Pts with a history of other malignancies or lacking records at least 1 year prior to diagnosis were excluded. Pts were considered AS if they received chemotherapy, interferon, ≥2 days of MM surgery, or a code of secondary metastases. All other pts were classified as ES. Radiotherapy, immunotherapy, chemotherapy, and surgery type were identified with HCPCS, CPT, and ICD9 procedure codes. Pts were categorized by type of progression (ToP): AS at time of dx (AS-D), ES at dx with progression to AS during follow-up (ES-P), and ES at dx with no progression during follow up (ES-NP). Results: Of 30,678 eligible pts, 55% were male, median age was 59 yrs, and median follow-up was 31 months. Initial disease locations were head and neck (21%), torso (27%), upper extremities (17%), and lower extremities (14%). Twenty-five percent (7607 pts) were identified as having AS MM during follow-up. Of these, 2,445 (8%) were AS-D, while 5162 (17%) were ES-P. The remaining 23,071 pts (75%) were ES-NP. Frequency of most extensive surgery type after diagnosis date are shown by ToP (table). No ES-NP pts received systemic tx during follow-up, but 21% of ES-P and 64% of AS-D pts received either chemotherapy, immunotherapy, or both. Agents most commonly prescribed in AS pts were interferon and temozolomide. Conclusions: The tx burden in MM pts is extensive and appears to increase with disease severity. Claims data can be a valuable tool in elucidating MM tx patterns by disease stage. [Table: see text]
Estrogen receptor (ER) signaling in normal, BRCA (B) 1 and B2 mutation associated, and ER-positive breast cancer (BC) mammary cells.
Authors: Elgene Lim, Housheng Hansen He, David Chi, Judy Ellen Garber, Andrea Richardson, Myles Brown
Journal: Journal of Clinical Oncology (2012)

576 Background: ER is expressed in ≈70% of sporadic BC and activates genes driving cell proliferation and tumorigenesis. B1 and B2 mutation associated BC have predominant triple negative and ER+ phenotypes respectively, yet hormonal manipulation with oophorectomy reduces BC risk in both B1 and B2 carriers. We have previously performed genome-wide analysis of ER binding sites in MCF-7 BC cells, and identified distinct mechanisms of ER signaling. Here, we seek to elucidate differences in ER signaling between non-malignant (normal, B1 and B2) and ER+ BC mammary cells. Methods: Breast tissue were obtained from patients undergoing reduction mammoplasties (normal), prophylactic mastectomies (B1 and B2 carriers) and surgical excision of ER+ BC. After dissociation into a single-cell suspension, ER+ EpCAM+CD49f- mature luminal (ML) and EpCAM+CD49f+ luminal progenitor (LP) subpopulations were obtained by flow cytometry. Following estrogen stimulation, RNA was extracted for gene microarray analysis. ER chromatin immunoprecipitation and DNA sequencing (ChIP-seq) was performed and DNA libraries prepared and sequenced. Results: Triplicates ofnormal, prophylactic B1 and B2, and ER+ BC tissues were analyzed.Gene ontology analysis indicates different gene expression signatures between non-malignant tissue and MCF-7 BC cells following estrogen stimulation. Genes that promotes cell cycling and proliferation were downregulated in non-malignant tissue, but were upregulated in BC cells (P &lt; 10 -5 ). Hierarchical clustering of the gene microarray by mutation status revealed distinct LP gene signatures in normal, B1 and B2 breast tissue, whilst the ML signatures were largely indistinguishable between the three tissue types. Conclusions: There are contrasting differences in ER signaling between normal mammary and BC cells, with estrogen having anti-proliferative effects in normal luminal cells compared to pro-proliferative effects in BC. Our data suggest that alterations in ER signaling play a major role in breast tumorigenesis. Differences in the LP population between B1 and B2 breast tissue may account for their distinct BC phenotypes.
Comparison of Accuracy of Patient and Physician Scar Length Estimates Before Mohs Micrographic Surgery for Facial Skin Cancers
Authors: William C. Fix, Christopher J. Miller, Jeremy R. Etzkorn, Thuzar M. Shin, Nicole Howe, Joseph F. Sobanko
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Patients are satisfied when surgical outcomes meet their expectations. Dissatisfaction with surgical scars is one of the most common reasons that patients sue surgeons who perform Mohs micrographic surgery (MMS). <h3>Objective</h3> To measure the accuracy of patient and physician estimations of scar length prior to skin cancer removal with MMS. <h3>Design, Setting, and Participants</h3> This cross-sectional study was conducted between December 1, 2017, and February 28, 2018, at the MMS clinic of a single tertiary referral center health system. A total of 101 adults presenting for MMS for treatment of facial skin cancers volunteered for this study, and 86 surgeons who performed the MMS procedure participated. <h3>Main Outcomes and Measures</h3> Patients and physicians independently drew the anticipated scar length on the patients' skin prior to surgery. Preoperative estimates by patients and surgeons were compared with actual postoperative scar length. <h3>Results</h3> Of the 101 patients who participated, 57 patients (56.4%) were men and 57 patients (56.4%) were aged 65 years or older. Eighty-four patients (83.2%) underestimated scar length, whereas 67 of the 86 surgeons (77.9%) correctly estimated the scar length (<i>P</i> &lt; .001). The actual postoperative scar length was 2.2 (interquartile range, 1.5-3.6) times larger than the patients' preoperative estimate but only 1.1 (interquartile range, 1.0-1.2) times larger than the surgeons' preoperative estimate (<i>P</i> &lt; .001). Preoperative consultation with the surgeon, a personal history of MMS, or patient-directed research about MMS were not associated with improvement of patients' estimations of scar length. <h3>Conclusions and Relevance</h3> This study's findings suggest that patients with facial skin cancers have unrealistic expectations regarding scars that measure, on average, less than half the length of the actual postoperative scars. Surgeons appear to accurately estimate the length of most surgical scars and have an opportunity to set realistic patient expectations about scar length before surgery.
Outcome of non small cell lung carcinoma patients receiving chemotherapy in Kartal State Hospital, Turkey
Authors: M. Kocak, A. Mayadagli, A. Ozkan, M. Gumus, A. Marti, O. Demir, C. Parlak, M. Aliustaoglu
Journal: Journal of Clinical Oncology (2006)

17142 Background: Lung cancer has been the leading cause of cancer deaths in men worldwide, and is the second most common cause of cancer deaths in women. Non-small cell histology comprises about 70–80% of every diagnosis of lung cancer. Despite advances in the detection and treatment, the long-term survival of patients with advanced non-small cell lung cancer (NSCLC) remains poor, with a 5-year survival of less than 5%. We conducted this trial to determine the influence of treatment with docetaxel given in combination with cisplatin on survival and time to progression, and to evaluate its tolerability in chemotherapy naive patients with metastatic NSCLC. Methods: Patients with histological or cytological confirmed stage IV NSCLC who met the following criteria were eligible for the study: suitable for first-line chemotherapy with no previous chemotherapy, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–2, an objective measurable disease, an adequate bone marrow reserve, a normal hepatic and renal function. Cisplatin and docetaxel were delivered to the patients at one dose level through the courses repeated every 3 weeks for 4–6 cycles. Each patient received docetaxel at the doses of 75 mg/m 2 /day and cisplatin at the doses of 75 mg/m 2 /day both on day 1. Results: Fifty eligible patients with stage 4 NSCLC were enrolled into the study from June 2003 to September 2005. Median follow-up time was 6 months (1–21). Median age was 61.5 (39–75). Forty eight patients (96%) were male, and 2 patients (8%) were female. Histological type was squamous cell carcinoma in 21 patients (42%), adenocarcinoma in 11 patients (22%) and undifferentiated histologies in 18 patients (36%). The median overall survival time was 16 months (95%CI: 8–24). One-year survival rate was 56.3%. Overall response rate was 44% with 40% partial (PR), 4% complete response (CR). Twenty eight percent of patients had stable disease, and 28% of patients showed disease progression. The median time to progression was 4 months (95%CI: 2.4–5.5). Conclusion: Docetaxel/cisplatin demonstrated efficacy comparable to other platinum agent doublets. No significant financial relationships to disclose.
LIPID MANAGEMENT IN ACUTE CORONARY SYNDROME PATIENTS AMONG THE TIER THREE HOSPITALS
Authors: Yong Huo, Yanjun Gong, Jie Jiang, Xitian Hu, Shaowen Liu, Yujie Zhou, Xuan Li, Xiang Ma, Hongwei Yu, Ying Li, Guochun Zhang, Bin Wang, Xiaoyong Qi, Haiyan Meng, Xiaofeng Wang, Jianjun Mu, Jingping Wang, Gang Liu, Zhenyu Yang, Xiangqing Kong, Yuhu Yan, Changqian Wang, Jian'An Wang, Wang Lijun, Jiyan Chen
Journal: Journal of the American College of Cardiology (2020)
Curative interstitial brachytherapy for early stage carcinoma of lip—A case report
Authors: A. K. Jha, G. Prasiko, H. Mod, P. P. Chaurasia, R. Shrivastava
Journal: Journal of Clinical Oncology (2006)

15547 Background: Brachytherapy is potentially useful in the treatment of carcinoma lip. Small cancers of the lip (less than 2 cm) are treated equally well with surgery or radiation therapy with excellent cosmetic and functional results seen in radiation therapy. Methods: We treated an 18-year old male diagnosed as stage 1 carcinoma lip with curative interstitial brachytherapy. Under anaesthesia, three catheters were inserted at 0.5 cm separation through the lesion. Patient was simulated, planned, treated in VARISOURCE (Varian, USA). He received dose of 3 Gy per fraction, two fractions per day at a minimum interval of 6 hours between the two fractions for 6 days. He therefore received a total dose of 36 Gy with High Dose Rate (HDR) Brachytherapy. During treatment, he received hyperalimentaion via naso-gastric tube with intravenous antibiotic prophylaxis. Results: Upper lip swelling occurred in first 12 hours of treatment and remained for 6 days that subsided subsequently. Catheters were removed on 6 th day of treatment. Scar formation occurred over the lesion in 1 month’s follow up. In next one month’s follow up, there was no clinical evidence of disease. Cosmetic result was satisfactory. At two months follow, the patient is clinically disease free and has no complaints. Conclusions: Interstiatial brachytherapy is a excellent method for treating early stage carcinoma lips with excellent cosmetic outcome. This kind of treatment is now available in my country at our institution. No significant financial relationships to disclose.
EVOLUTION OF ACUTE INTRAMURAL HEMATOMA
Authors: Arturo Evangelista-Masip, Raffi Bekeredjian, Eric M. Isselbacher, Alan C. Braverman, Marek Ehrlich, Santi Trimarchi, Eduardo Bossone, Mark Peterson, Daniel G. Montgomery, Derek Brinster, Davide Pacini, Truls Myrmel, Edward P. Chen, Takeyoshi Ota, Thomas G. Gleason, Kim Eagle, Kevin Harris
Journal: Journal of the American College of Cardiology (2020)
531MO VHIO immune gene-expression signature (VIGex) to enrich patient selection in immunotherapy (IT) phase I clinical trials
Authors: A. Hernando-Calvo, F.M. Mancuso, I. Braña, O. Saavedra Santa Gadea, M. Vieito, G. Alonso Casal, V. Galvao de Aguiar, A.B. Azaro Pedrazzoli, I. Matos, R. Berché, N. Ann Worham, C. Saura, G. Argiles Martinez, E. Elez, E. Munoz Couselo, E. Felip, J. Seoane, J. Tabernero, A. Vivancos, E. Garralda
Journal: Annals of Oncology (2020)
THE UTILITY OF POSITRON EMISSION TOMOGRAPHY (PET) MYOCARDIAL PERFUSION IMAGING (MPI) IN THE ASSESSMENT OF CORONARY ARTERY DISEASE IN PATIENTS WITH APICAL HYPERTROPHIC CARDIOMYOPATHY: FRIEND OR FOE?
Authors: Michel Ibrahim, Maya Serhal, Stephanie Feldman, Shivda Pandey, Alice Jacobs
Journal: Journal of the American College of Cardiology (2020)